CN
Search Within
P2116
应用筛选条件
关键词:'P2116'
显示 1-30 共 76 条结果 关于 "P2116" 范围 论文
Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro
Stahnke T, et al.
Testing, 12(2), e0172592-e0172592 (2017)
Pirfenidone for IPF: pro/con debate; the 'con' viewpoint.
Ganesh Raghu et al.
Thorax, 68(7), 605-608 (2013-03-07)
[Antifibrotic treatment].
D von der Beck et al.
Deutsche medizinische Wochenschrift (1946), 139(49), 2523-2525 (2014-11-26)
Kong-hai Ni et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 990, 181-184 (2015-04-17)
In this study, a simple, sensitive, and robust analytical method based on ultra-performance liquid chromatography (UPLC) has been developed for the determination of trifolirhizin in rat plasma using pirfenidone as internal standard (IS). After sample preparation by a simple liquid-liquid
Monique E Cho et al.
Expert opinion on investigational drugs, 19(2), 275-283 (2010-01-07)
Many chronic diseases of various etiologies lead to fibrosis and organ dysfunction. Despite many advances in medicine in recent years, options to slow the progression of fibrotic diseases have remained limited. The recent availability of pirfenidone, an antifibrotic and anti-inflammatory
Tong Guo et al.
Alternatives to laboratory animals : ATLA, 42(4), 235-243 (2014-10-08)
Pulmonary fibrosis is a progressive and irreversible disorder with no appropriate cure. A practical and effective experimental model that recapitulates the disease will greatly benefit the research community and, ultimately, patients. In this study, we tested the lung slice culture
Takekazu Iwata et al.
Surgery today, 45(10), 1263-1270 (2014-11-22)
Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an
Pirfenidone in respirable powder form for the treatment of pulmonary fibrosis: a safer alternative to the current oral delivery system?
Satomi Onoue et al.
Therapeutic delivery, 4(8), 887-889 (2013-08-08)
Roberto Ramos-Mondragón et al.
Cardiovascular research, 96(2), 244-254 (2012-08-01)
On the basis of its ability to inhibit fibrosis, pirfenidone has drawn the attention as an intriguing candidate for treating cardiac disease. However, its precise electrophysiological effects have yet to be elucidated. Here, we have investigated its potential to modulate
Natalie J Carter
Drugs, 71(13), 1721-1732 (2011-09-10)
Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks administered to patients with IPF was associated with a significantly lower
Amrita Dosanjh
European journal of pharmacology, 536(3), 219-222 (2006-04-04)
Pirfenidone has a simple chemical structure, but may have profound implications for transplantation management. One of the leading causes of allograft failure is chronic allograft dysfunction, manifested by chronic inflammation and chronic fibrosis [Estenne, M., Hertz, M.I., 2002. Bronchiolitis obliterans
Idiopathic pulmonary fibrosis.
Owen J Dempsey et al.
BMJ (Clinical research ed.), 347, f6579-f6579 (2013-11-10)
Guoying Sun et al.
Molecular vision, 17, 2191-2196 (2011-08-26)
Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a new, broad-spectrum agent that has an inhibition effect on the proliferation, migration, and collagen contraction of human Tenon's fibroblasts, and thus modulating the wound healing process of glaucoma filtering surgical site. This study investigated the pharmacokinetics
Hyun-Jong Cho et al.
Small (Weinheim an der Bergstrasse, Germany), 17(14), e2007425-e2007425 (2021-03-11)
Despite considerable efforts in modeling liver disease in vitro, it remains difficult to recapitulate the pathogenesis of the advanced phases of non-alcoholic fatty liver disease (NAFLD) with inflammation and fibrosis. Here, a liver-on-a-chip platform with bioengineered multicellular liver microtissues is
Xian-Hong Xiang et al.
Molecular medicine reports, 12(1), 309-314 (2015-03-05)
Pirfenidone (esbiret) is an established anti-fibrotic and anti-inflammatory drug used to treat idiopathic pulmonary fibrosis. In the present study, the dose-dependent effects of pirfenidone on the cell cycle, proliferation and expression of heat shock protein (HSP)-47 and collagen type I
Peyman Bizargity et al.
Transplantation, 94(2), 114-122 (2012-06-30)
Pirfenidone (PFD) is an antifibrotic agent with beneficial effects on proinflammatory disorders. In this study, we further investigated PFD and long-acting form, "deuterated PFD," immune-modulating properties by evaluating their effects on mouse dendritic cells (DCs). The effects of PFD on
Yoshiki Seto et al.
Journal of photochemistry and photobiology. B, Biology, 120, 44-51 (2013-02-20)
Pirfenidone (PFD), an idiopathic pulmonary fibrosis drug, has phototoxic risk in clinical use, although its detailed mechanisms for the phototoxicity have never been fully elucidated. In the present study, the photochemical properties and in vitro phototoxicity of PFD were evaluated
Koji Takakura et al.
Renal failure, 34(10), 1309-1316 (2012-09-26)
Renal fibrosis is a common cause of renal dysfunction with chronic kidney disease. We previously investigated the renoprotective effects of the antifibrotic agent pirfenidone in a rat model of subtotal nephrectomy. Here, we further evaluated the antifibrotic effects of pirfenidone
Ole Hilberg et al.
The clinical respiratory journal, 6(3), 131-143 (2012-06-16)
Pirfenidone has been shown in three recently published trials to slow down the progression of the devastating interstitial lung disease, idiopathic pulmonary fibrosis (IPF). The precise mechanisms that initiate and perpetuate the histopathological process leading to lung fibrosis in IPF
J Behr et al.
Deutsche medizinische Wochenschrift (1946), 137(49), 2586-2588 (2012-11-29)
Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia, is with a prevalence of 2-29 cases per 100,000 individuals a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly
Inge M Westra et al.
Toxicology and applied pharmacology, 274(2), 328-338 (2013-12-11)
Induction of fibrosis during prolonged culture of precision-cut liver slices (PCLS) was reported. In this study, the use of rat PCLS was investigated to further characterize the mechanism of early onset of fibrosis in this model and the effects of
A new hope for idiopathic pulmonary fibrosis.
Gary M Hunninghake
The New England journal of medicine, 370(22), 2142-2143 (2014-05-20)
Kihwang Lee et al.
Current eye research, 39(7), 680-685 (2014-01-10)
The effects of pirfenidone were investigated on cultured human pterygium fibroblasts (HPFs). HPFs were obtained from pterygium surgery and subjected to primary culture. After treatment with 0.5, 1.0 or 1.5 mg/mL pirfenidone, MTT and cell migration assays were performed, and procollagen
Luca Richeldi et al.
Expert review of respiratory medicine, 5(4), 473-481 (2011-08-24)
Idiopathic pulmonary fibrosis is the most lethal form of diffuse lung fibrosis, killing approximately half of those affected within 2-3 years of diagnosis. Until recently, no therapies had been shown to have an impact on disease progression. The Clinical Studies
Chunguo Jiang et al.
PloS one, 7(10), e47024-e47024 (2012-10-12)
Pirfenidone (PFD) is a novel antifibrotic agent approved for patients with pulmonary fibrosis. However, there are concerns regarding toxicity of the drug. In this meta-analysis, we analyzed the adverse events (AEs) of PFD for the treatment of pulmonary fibrosis. We
Yasmina Bauer et al.
American journal of respiratory cell and molecular biology, 52(2), 217-231 (2014-07-17)
The bleomycin-induced rodent lung fibrosis model is commonly used to study mechanisms of lung fibrosis and to test potential therapeutic interventions, despite the well recognized dissimilarities to human idiopathic pulmonary fibrosis (IPF). Therefore, in this study, we sought to identify
InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs.
Katie Kingwell
Nature reviews. Drug discovery, 13(7), 483-484 (2014-07-02)
Pathobiology of Novel Approaches to Treatment
AIDS Patient Care and STDs, 26(146), 170057-170057 (2018)
Sabrina Bajwah et al.
Thorax, 68(9), 867-879 (2012-12-04)
Patients with fibrotic interstitial lung disease have symptom control and quality of life (QoL) needs. This review aims to evaluate the evidence for the use of interventions in improving dyspnoea, other symptoms and QoL. Eleven databases, relevant websites and key
Prescrire international, 22(138), 117-119 (2013-07-03)
Idiopathic pulmonary fibrosis is a rare disorder due to progressive, widespread fibrotic damage of the lung parenchyma. It usually occurs after the age of 50, and its cause is unknown. Symptoms include progressive shortness of breath and nonproductive cough. The
1/3